Small Interfering RNA (siRNA) Therapeutics Size, Share, and Industry Analysis, By Product (Fitusiran, Patisiran, Givosiran, Lumasiran, Inclisiran, Vutisiran, and Others), By Disease Indication (Hereditary Transthyretin Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 (PH1) Clinical Atherosclerotic Cardiovascular Disease, and Others), By Route of Administration (Intravenous, Subcutaneous, and Others), By Age (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

The global small interfering RNA (siRNA) therapeutics market is witnessing substantial growth due to a rise in investment for research and development that advances treatments with enhanced delivery, stability, and efficacy of small interfering RNA. Small Interfering RNA represents a class of molecules capable of regulating gene expression and protein production. These molecules are designed to prevent the production of disease-causing proteins by targeting the messenger RNA (mRNA) that encodes for such proteins. Therapeutic small interfering RNAs (siRNAs) are double-stranded RNAs that silence genes by activating the RNA interference pathway (RNAi). These double-stranded RNAs allow the design of potent siRNAs for specific gene silencing. 

A rise in investment and funding activities led to the development of numerous pipeline candidates to meet the rising demand. Due to such rising demand for small-interfering RNA therapeutics, many established players focus on strategic activities such as acquisition and collaboration to propel the market's growth.

• For instance, in April 2025, Ono Pharmaceutical Co., Ltd entered a research collaboration agreement with Jorna Therapeutics, aimed at drug discovery using a ribonucleic acid (RNA) editing platform. 
• Similarly, in July 2023, Novartis AG acquired DTx Pharma to leverage its trademarked FALCON platform to develop siRNA therapies for neuroscience indications.

Small Interfering RNA Therapeutics Driver

Increasing Collaboration with the Operational Entities and Technological Advancement to Drive the Growth of the Market

The rising demand for personalized medicine and the need for effective alternative treatments resulted in effective siRNA therapies. To support this rising demand, various operational entities in the market are undergoing strategic activities such as collaboration and acquisitions. Such developments are expected to steer the market growth. 

• For instance, in May 2025, AbbVie Inc. collaborated with ADARx Pharmaceuticals and agreed to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology, and oncology. Under the agreement, ADARx is expected to receive a USD 335.0 million upfront payment and will be eligible to receive several billion dollars in additional contingent payments, including option-related fees, milestone payments, and tiered royalties. Such strategic collaborations and investment is expected to drive the market's growth. 

Furthermore, technology integration, such as machine learning and artificial intelligence, supports the market's growth.

• For instance, in October 2024, Eli Lilly collaborated with Insitro to develop treatments for metabolic diseases, combining Insitro's artificial intelligence (AI) machine learning (ML) platform with Lilly's drug delivery technology. The GalNAc technology, which is widely used as a delivery method for siRNA therapies, will be used by Insitro to improve the treatment of conditions such as metabolic dysfunction-associated steatotic liver disease (MASLD).

Prevalence of Primary Hyperoxalurias (PH), By Type (% per million population)

In January 2020, Orphanet updated its report that stated the prevalence of Primary Hyperoxalurias (PH) ranges from 1 to 3 patients per 1,000,000 population. In which PH1 accounted for 85.0% of patients, PH2 8.0-10.0% and PH3 5.0-7.0%. Such a high incidence of PH1, which are treated with siRNA, is expected to support the growth of the market.

Small Interfering RNA Therapeutics Restraint

Off-Target Effects of Small Interfering RNA to Restrict Growth Potential

One of the major concerns in siRNA therapeutics is off-target effects and unintended gene expression. Often, clinical trials face failure due to off-target effects, such as off-target gene dysregulation. This could result in potential toxic side effects. These factors can restrict the growth of the market in the forecasted years.

• For instance, in January 2022, NIH published an article titled ‘The siRNA Off-Target Effect Is Determined by Base-Pairing Stabilities of Two Different Regions with Opposite Effects’ reported that the off-target effect is induced through stable base-pairing between the siRNA seed region and off-target mRNAs, but not induced through unstable base-pairing.

Also, adverse effects associated with administering therapeutic siRNA molecules, such as injection site reactions, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in the extremities, and dyspnea, could hamper the market growth. 

Small Interfering RNA Therapeutics Opportunity

Emergence of Combination Therapies Using Small Interfering RNA for the Therapeutic Treatment of Cancer to Offer Avenues for Market Growth

Integration of the siRNA therapeutics with other pharmacological modalities such as molecule drugs, antibodies, or even gene editing technologies, combining oligonucleotides, is part of the combination therapies. These advancements expand the application areas of siRNA therapeutics in various verticals such as infectious disease, cancer, and cardiovascular diseases. Research and development in the therapeutic application for siRNA offer greater expansion avenues for growth.

• For instance, in August 2023, Sirnaomics announced a successful phase I clinical study of RNAi therapeutic STP707 for treating multiple solid tumors. STP707 is composed of two siRNA oligonucleotides demonstrated to inhibit the expression of their target mRNAs, and combining the two siRNAs produces a synergistic effect that diminishes pro-inflammatory factors. The results from this basket study encouraged exploring STP707 as a potential single drug or a combination treatment with immune checkpoint inhibitor drugs. Such opportunities are expected to offer lucrative growth opportunities for the market.

Key Insights

The report covers the following key insights:

• Pipeline Analysis, By Key Players 
• Technological Advancements in the Market
• Regulatory and Reimbursement Scenario, by Key Countries/ Regions
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Product

By product, the market is divided into Fitusiran, Patisiran, Givosiran, Lumasiran, Inclisiran, Vutisiran, and Others.

The inclisiran segment is expected to grow significantly in the forecast period of the global small-interfering RNA therapeutics market. The high market share of the product is attributed to recent marketing approvals by regulatory bodies.

• For instance, in December 2021, Novartis AG received approval from the U.S. FDA for administering Leqvio (inclisiran), a small interfering RNA (siRNA) therapy used to lower low-density lipoprotein cholesterol with two yearly doses. These factors are expected to fuel the market growth. Such developments are expected to catalyze the growth of the market.

Analysis by Disease Indication

By disease indication, the global small interfering RNA therapeutic market is classified into hereditary transthyretin amyloidosis (hATTR), acute hepatic porphyria (AHP), primary hyperoxaluria type 1 (PH1), clinical atherosclerotic cardiovascular disease (ASCVD), and others. 

Among these, clinical atherosclerotic cardiovascular disease (ASCVD) is expected to hold a considerable position due to its high prevalence in comparison to other disease indications that utilize small interfering RNA for treatment. Additionally, many companies are investing profoundly in developing new therapies for the disease indication.

• For instance, in May 2025, Sirius Therapeutics Inc. raised nearly USD 50.0 million in a series B2 financing round to support its pipeline of small interfering RNA (siRNA) molecules for cardiovascular disease indications. The main siRNA candidate, SRSD-107, is a long-acting Factor XI anticoagulant for thromboembolic disorders. Such a high investment in the segment is expected to support the segmental growth in the market. 

Analysis by Route of Administration

Based on route of administration, the small interfering RNA therapeutics are further divided into subcutaneous and intravenous, and others. 

The subcutaneous segment is expected to grow substantially over the forecast period. Various research and development, along with new product launches, are being focused on the subcutaneous route of administration. Furthermore, regulatory approvals for subcutaneously administered siRNA therapeutics are also expected to support segmental growth. 

• For instance, in March 2025, Rona Therapeutics Inc. received clearance of an Investigational New Drug (IND) by the U.S. FDA for RN0361, an APOC3-targeted siRNA (small interfering RNA) therapeutic for the treatment of severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS). The candidate enabled hepatocyte-specific silencing via subcutaneous administration. Such developments are expected to strengthen the segment's market share. 

Analysis by Age

Based on age, the market is further classified into pediatrics and adults. The adult segment is expected to hold a substantial market share. The high market share of the adult segment is attributed to the availability of numerous U.S. FDA-approved products. 

• For instance, in March 2025, Alnylam Pharmaceuticals, Inc. received approval from the U.S. FDA for its RNAi therapeutic, AMVUTTRA (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. Such developments are expected to boost the segmental growth.

 Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

Hospital pharmacies are expected to hold a significant market share. The high market share of hospital pharmacies is expected due to increasing participation of hospital pharmacies in providing inpatient and outpatient care for patients. 

• For instance, in 2024, the American Society of Health System Pharmacists conducted a poll from 250 hospital pharmacy directors and reported that pharmacists routinely provide clinical services to the majority of their hospital's inpatients. Such high participation by the hospital pharmacy propels the growth of the segment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest share of the global small interfering RNA (siRNA) therapeutics market in 2024. The growth of the market in the region is attributed to the increasing number of clinical trials and ongoing research to boost the growth of the siRNA therapeutics market.

Moreover, marketing approvals by the various regulatory bodies in the region to drive the market growth in the forecasted years. 

• For instance, in March 2025, Alnylam Pharmaceutical Inc. received approval for Qfitlia (fitusiran) by the U.S. FDA for treatment of routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B with or without factor VIII or IX inhibitors. Qfitlia is a small-interfering RNA therapeutic that utilizes conjugate technology—such developments to catalyze growth in the region.

Europe is expected to grow with a considerable CAGR during the forecast period. The region's high market share is due to high investment in research initiatives. Many established players in the region are focusing on optimizing their product offerings and expanding the production capacity of small-interfering RNA to meet the rising demand in the region. 

• For instance, in April 2025, Silexion Therapeutics Corp. collaborated with Catalent to develop formulation and clinical manufacturing activities for Silexion's next-generation siRNA candidate, SIL204, in France. The collaboration focused on optimizing the systemic and intratumoral delivery formulations of SIL204. 

Asia Pacific is expected to grow with a substantial CAGR during the forecast period. The regional growth is attributed to the various strategic activities, such as commercialization agreements and collaboration within the operational entities in the region. 

• For instance, in April 2024, Chugai Pharmaceutical Co., Ltd. signed a license agreement with Roche for zilebesiran, an investigational siRNA therapeutic indicated for hypertension. The license agreement provided Chugai Pharmaceutical Co., Ltd with exclusive commercialization rights in Japan for zilebesiran. Such developments are expected to drive the growth of siRNA treatments in the Asia Pacific region.

Key Players Covered

The global small-interfering RNA therapeutics market is semi-consolidated with the presence of a few groups and a large number of emerging companies.

The report includes the profiles of the following key players:

• Alnylam Pharmaceuticals, Inc. (Cambridge, U.S.)
• AbbVie Inc. (North Chicago, U.S.)
• Boehringer Ingelheim International GmbH. (Ingelheim, Germany)
• Novo Nordisk A/S (Bagsvaerd, Denmark)
• Novartis AG (Basel, Switzerland)
• Sirnaomics (Gaithersburg, U.S.)
• Regeneron Pharmaceuticals Inc. (New York, U.S.)
• Arrowhead Pharmaceuticals, Inc. (Pasadena, U.S.)

Key Industry Developments

• In November 2024, Sarepta Therapeutics, Inc., collaborated with Arrowhead Pharmaceuticals, Inc. for an exclusive global licensing agreement. The agreement provided the company with exclusive global rights to multiple clinical, preclinical, and discovery-stage siRNA programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs.
• In January 2024, Boehringer Ingelheim International GmbH. collaborated with Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The collaboration aimed for clinical development of small interfering RNA (siRNA) therapeutics for cardiovascular, renal, and metabolic diseases (CRM).